NuGen Receives “Insulin Specific” Health Canada Approval
NuGen Medical Devices (TSXV:NGMD) Receives Additional “Insulin Specific” Health Canada Approval for the InsuJetTM
- NuGen’s needle-free injection system, the InsuJetTM, has been approved by Health Canada specifically for the needle-free delivery of insulin
- The company previously received Health Canada approval for general use of the needle-free system
- This is the first ever insulin specific needle-free injection system approved by Health Canada for sale to the healthcare system and its end users
- The approval may also aid in the process of obtaining coverage for the system by certain health care insurance providers in Canada
NuGen M.D. has announced that its needle-free injection system, the InsuJetTM, has been approved by Health Canada specifically for the needle-free delivery of insulin.
This announcement builds on the company’s previous approval from Health Canada, announced on December 9, 2021, which allowed the InsuJetTM to be marketed for general use.
“This additional Health Canada approval brings more clarity to the intended use of the device and will further support our marketing initiatives to the diabetic community,” said NuGen CEO Michael Wright. “Our goal is to have our technologies accessible not only to the diabetic community, but to give all patients that are currently burdened with injecting themselves with a needle the option of using a needle-free device.”
The company stated that, to the best of its knowledge, this is the first ever insulin specific needle-free injection system approved by Health Canada for sale to the healthcare system and its end users.
“This is another important milestone in paving the way for diabetics in Canada to be able to easily acquire and use our needle-free injection device to deliver pain-free and fear-free insulin,” said Mr. Wright.
In addition to allowing NuGen M.D. to market its devices to diabetics in Canada, this approval may also aid in the process of obtaining coverage for the system by certain health care insurance providers in Canada.
The InsuJet™ is currently approved in over 40 countries and is available through distributors in The Netherlands, United Kingdom, Taiwan, Hong Kong, Australia, Brazil and many Middle Eastern countries, amongst others.
NuGen Medical Devices is an emerging specialty medical device company focused on developing and commercializing novel drug delivery technologies.
Shares in NuGen M.D. (NGMD) are currently up 9.52% on the TSXV, trading at CA$0.115 per share.
To learn more about NuGen M.D. and its products, visit the Company’s website. To read the full press release, click here.
About the Kinvestor Network
The Kinvestor Network is an exclusive network of investors that want access to enhanced research and reporting. Members of the Kinvestor Network have access to exclusive articles, reports, models and various other tools that investors may find useful.
Visit the Kinvestor Network for more free content, including in-depth research reports, industry documentaries, CEO interviews, and more.
Please read this disclaimer in its entirety before reviewing any opinions, views or information expressed by Kin Communications Inc. (“Kin”).
